Table 4.
Diagnostic performance of circulating markers for iCCA patients with negative CA19-9.
| Markers | iCCA Cohort with Negative CA19-9 (n = 149) vs. Control (n = 571) | |||||
|---|---|---|---|---|---|---|
| AUC (95% CI) | NPV (%) | PPV (%) | Sensitivity (%) | Specificity (%) | p | |
| miR-21 | 0.771 (0.739–0.802) | 83.4 | 80.4 | 77.2 | 65.8 | <0.001 |
| miR-122 | 0.712 (0.677–0.725) | 81.8 | 82.1 | 63.8 | 74.1 | <0.001 |
| 2-miR model * | 0.794 (0.762–0.823) | 85.5 | 84.4 | 70.5 | 77.6 | <0.001 |
| 3-marker model # | 0.795 (0.763–0.824) | 85.9 | 85.1 | 76.5 | 72.7 | <0.001 |
* Logit (p = iCCA) = −9.289 + (0.793 × miR-21) + (0.353 × miR-122); # Logit (p = iCCA) = −9.967 + (0.777 × miR-21) + (0.389 × miR-122) + (0.004 × CA19-9); AUC, Area Under Curve; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.